Amniotic fluid testosterone and follicle-stimulating hormone assay in the prenatal determination of fetal sex

A Cross-Sectional Study of Female Sexual Function and Dysfunction During Pregnancy

INTRODUCTION

Although women may undergo changes in sexual function during pregnancy, there are limited studies correlating possible sexual function changes to androgen blood levels during the pregnancy.

AIM

To search for a possible correlation, we performed a cross-sectional observational study to assess sexual function scores and androgen blood levels of women during pregnancy.

MATERIALS AND METHODS

A total of 589 healthy pregnant women were recruited to the present cross-sectional study. Of these patients, 116 (19.6%), 220 (37.3%), and 253 (42.9%) were in their first, second, and third trimesters, respectively. They were evaluated with a detailed medical and sexual history, including IFSF questionnaire. In addition, maternal serum androgen levels (testosterone, dehydroepiandrosterone sulphate, free testosterone) were determined in each trimester during regular follow-ups.

MAIN OUTCOME MEASURES

Assessment of Index of Female Sexual Function (IFSF) domains and serum androgen levels in each trimester.

RESULTS

The mean age of the three groups were similar (P > 0.05). Overall, total IFSF scores of women in the first and second trimesters were 21.4 +/- 10.1 and 22.3 +/- 10, respectively, while it was 15.9 +/- 12.3 during the third trimester (P < 0.05). The most common sexual dysfunction symptom was diminished clitoral sensation, observed in 94.2% of the patients, followed by lack of libido in 92.6% and orgasmic disorder in 81%. No correlation was detected between total IFSF score and serum androgen levels.

CONCLUSION

In this cross-sectional study, we noted lower sexual function scores in women in the third trimester of their pregnancies compared with those in their first two trimesters of pregnancy. These lower sexual function scores in the third trimester were not associated with lower androgen levels. We plan to perform a future prospective study to better assess both the change in sexual function and also its possible relation to androgen levels in pregnant women.

On a possible early identification procedure for babies at high risk for autistic spectrum disorder

A hypothesis for a method that may make possible the early identification of neonates at high risk for later development of autistic spectrum disorder (ASD) is set forth. The method is a test of the assertion that unusually high testosterone concentrations in amniotic fluid (TECAFs) are predictive of later ASD diagnoses. The statistical distribution of TECAFS, obtained in the 14-20th week of pregnancy, is used to determine the critical TECAF value above which the highest 2% lie and thus identify the babies at high risk for later ASD syndromes. From presently available data a single numerical value cannot be obtained. However, a critical value calculated from the mean TECAF value of a group of gender identified amniotic fluid samples, which are all assayed by the same technique, and multiples of the standard deviation (SD) of the TECAFs of that group, leads to an estimate of the critical TECAF value. We estimate that this critical value is equal to the mean plus 2.6 times the standard deviation, (m+2.6 SD), of the set of measurements. A rough calculation of the number of neonates that would be needed for a test of this method is discussed.

A window for the study of prenatal sex hormone influences on postnatal development

In humans, the influence of prenatal sex hormones on the fetal brain and subsequent postnatal development has had limited study because of the apparent inaccessibility of hormone levels in normal fetuses. We propose that amniotic fluid obtained via midtrimester amniocentesis can be assayed for fetal hormone levels during the period thought to be important for sexual differentiation of the brain. Amniotic fluid samples from midgestation (N = 70) were assayed for levels of testosterone and follicle-stimulating hormone, and significant sex differences were observed (ps less than .001), with some degree of overlap between the sexes. The possibility of applying hormone levels obtained from amniotic fluid to the study of postnatal development is discussed.

Amniotic fluid testosterone and testosterone glucuronide levels in the determination of foetal sex

Unconjugated testosterone levels were assayed in 351 amniotic fluid samples obtained at 15-19 weeks gestation. The median values for unconjugated testosterone in the 166 female foetuses and 185 male foetuses were 137 and 712 pmol/l respectively. Sixteen amniotic fluid samples from male foetuses had unconjugated testosterone levels lower than the highest female unconjugated testosterone value (361 pmol/l). Testosterone glucuronide was measured in amniotic fluid from 48 female and 55 male foetuses. There was a significant sex difference in the median values of testosterone glucuronide between female (median 160 pmol/l, range 64-465 pmol/l) and male (median 817 pmol/l, range 68-3707 pmol/l) amniotic fluid specimens (P less than 0.001). Of the sixteen male foetuses with amniotic fluid unconjugated testosterone levels in the female range, 12 had amniotic fluid testosterone glucuronide levels within the male testosterone glucuronide range of values. Hence used in conjunction with unconjugated testosterone, testosterone glucuronide increased the predictive accuracy of foetal sexing from 95.4 to 98.9%. Testosterone sulphate was measured in 24 female and 25 male amniotic fluid samples. There was no Testosterone sulphate was measured in 24 female and 25 male amniotic fluid samples. There was no significant difference between female (median 2591 pmol/l) and male (median 2964 pmol/l) testosterone sulphate levels.

Fetal sex dependent hormone levels in early pregnant women with elevated maternal serum alpha-fetoprotein

Maternal serum and amniotic hormone levels have been investigated in two groups of women in pregnancy weeks 18-21. One group (B) was composed of women with high alpha-fetoprotein levels in serum without fetal abnormality, and a matched control group (A) with normal alpha-fetoprotein levels in serum. Amongst group B women were four pregnancy complications: two spontaneous abortions, one premature delivery, and one cesarean section due to fetal asphyxia. Group B women were significantly different from group A women. Thus, higher maternal serum levels of total estriol (P = 0.030), testosterone (P = 0.016), and alpha-fetoprotein (P = 0.018) were noted in the presence of male fetuses; and higher hPL (P = 0.004), FSH (P = 0.037), and alpha-fetoprotein (P = 0.002) concentrations in women carrying female fetuses, who were accompanied by lower total estriol concentrations (P = 0.045). Differences between groups B and A in terms of amniotic fluid analyses were only related to female fetal sex. Thus, group B showed higher hPL (P = 0.028), testosterone (P = 0.020), and FSH (P = 0.006) levels, and lower alpha-fetoprotein (P = 0.013) concentrations. It is concluded that elevated maternal serum levels of alpha-fetoprotein are accompanied in female fetuses by an endocrine milieu different from that of matched controls. This difference may put the conceptus at a disadvantage, but the majority of the girls were born on time without signs of small-for-date.

Prenatal diagnosis--a compilation of diagnosed conditions

This article provides physicians with an up-to-date listing of 182 fetal conditions diagnosed prenatally. This information is presented in two key tables: the first an alphabetical listing of the conditions and the second a grouping of them according to disease categories. The latter table also presents the technique(s) used to establish the diagnosis, as well as pertinent references. Chromosomal abnormalities, diagnosed from amniotic fluid cell karyotypes, have not been individually tabulated in either table. Current techniques utilized for prenatal diagnosis are presented (see Comment).

Changes in maternal serum total and free androgen levels in early pregnancy: lack of correlation with fetal sex

The fetal testis actively produces androgens during early gestation. To determine whether this fetal production of androgens might be reflected by levels of androgens in maternal serum, which might then be a useful test for antenatal fetal sex determination, we measured serum testosterone (total and free) and serum dihydrotestosterone in 83 pregnant women whose fetuses ranged from 4 to 20 weeks in age. For no maternal serum androgen measured was there a significant difference between women carrying a male fetus and those carrying a female fetus, even when this comparison was limited to various 4-week subintervals or fetal age. Total serum testosterone correlated directly with fetal age (r = 0.341, p less than 0.005), but serum dihydrotestosterone did not (r = 0.146, p = NS). Inverse correlations with fetal age were observed for percentage free testosterone (r = -0.531, p less than 0.001) as well as absolute serum free testosterone (r = -0.349, p less than 0.005). We conclude that maternal serum androgen levels are not useful for antenatal fetal sex determination in early pregnancy. The reason for the progressive fall in serum free testosterone, and presumably androgen production, during early gestation remains obscure.